Products - Ovarian cancer | Topic | NICE

Showing 11 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (including a review of technology appraisal no. 381) [ID1296]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 October 2019
Rucaparib for maintenance treatment of recurrent platinum-sensitive epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1485]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 October 2019
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for maintenance treatment of ovarian, fallopian tube or peritoneal cancer that has a BRCA germline mutation after response to first-line platinum-based chemotherapy [ID1124]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC